Regeneron's Libtayo gets CHMP backing for less frequent EU dosing
What's the deal? Regeneron announced on 16 October 2026 that the European Medicines Agency's human medicines committee (CHMP) adopted a positive opinion recommending approval of an updated dosing regimen for its cancer immunotherapy Libtayo (cemiplimab) across all approved indications in the European Union. The recommendation supports giving Libtayo at a higher dose (700 mg) as a 30-minute infusion every six weeks after an initial 12-week regimen of 350 mg every three weeks. It also supports shortening the infusion time for the 350 mg dose to 15–30 minutes — roughly half the current time — after a first, well-tolerated infusion.
Why it matters: Libtayo is a PD-1 checkpoint inhibitor — a therapy that helps the immune system recognise and attack cancer cells — approved in the EU across six indications including certain skin, lung and cervical cancers. Fewer hospital visits and shorter infusions matter for patients on long-term cancer therapy and for the clinics delivering it. The 700 mg every-six-weeks schedule is already approved in the EU as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma; this opinion would extend the regimen to all approved indications. The European Commission is expected to make a final decision in the coming months. The positive opinion is supported by pharmacokinetic and pharmacodynamic modelling and simulation, integrated with clinical safety and efficacy data from Libtayo's development programme.
Read more: Regeneron, 16 October 2026 · EMA, 16 October 2026